.Nature Medication, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin led to boosted progression-free as well as overall survival, causing FDA approval as well as a new therapy option for individuals.